RE:Roche’s 3-for-1 opportunity clearly, I don't know why big pharmas are so stubborn with immunotherapy. They will have jaw-dropping reaction when they see the efficacy of our ACT platform.
By the way, Roche's partner Exelixis is worth 5.3B$US, at its 52-week low.
Roche, Exelixis' Tecentriq-Cabometyx pair fails again—this time in kidney cancer
Roche and Exelixis’ combination of Tecentriq and Cabometyx just can't win. After stumbling in liver cancer and lung cancer, the regimen has failed again.
Pairing Tecentriq with Cabometyx couldn’t further stave off cancer progression or death compared with Cabometyx alone in kidney cancer patients who’ve progressed on initial immunotherapy. The negative result came from the phase 3 Contact-03 trial. Exelixis announced the flop Thursday in a short release without many details other than stating that the data will be presented at an upcoming conference.
Exelixis’ stock price at some point dropped nearly 9% because of the news during after-hours trading on Thursday. The price decreased about 4% Friday morning. But William Blair analyst Andy Hsieh, Ph.D., argued that investors were overreacting. To Hsieh, the trial flop has a different significance for each drug.
The combo’s flop, depending on detailed data, may buttress Cabometyx as the most appropriate tyrosine kinase inhibitor (TKI) in kidney cancer, Hsieh said. Before Contact-03’s readout, Calithera Biosciences’ now-discontinued glutaminase inhibitor telaglenastat also failed to improve upon Cabometyx in a randomized clinical trial, he noted.
https://www.fiercepharma.com/pharma/roche-exelixis-tecentriq-cabometyx-pair-fails-again-time-kidney-cancer